NVCR (NovoCure) Total Liabilities: $457.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVCR NovoCure Ltd NVCR
70 GF Score
Price $15.68
GF Value $18.29
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is NovoCure Total Liabilities?

NovoCure NVCR -2.21% 70 Total Liabilities is $457.1 Mil as of Jun. 2026. GuruFocus rates NVCR with a GF Score™ of 70/100 and a GF Value™ of $18.29 (Modestly Undervalued). The stock has 4 warning signs investors should review.

NovoCure's Total Liabilities for the quarter that ended in Jun. 2026 was $457.1 Mil.

NovoCure's quarterly Total Liabilities declined from Dec. 2025 ($463.86 Mil) to Mar. 2026 ($457.21 Mil) and declined from Mar. 2026 ($457.21 Mil) to Jun. 2026 ($457.10 Mil).

NovoCure's annual Total Liabilities increased from Dec. 2023 ($783.63 Mil) to Dec. 2024 ($880.61 Mil) but then declined from Dec. 2024 ($880.61 Mil) to Dec. 2025 ($463.86 Mil).

NovoCure Total Liabilities Historical Data

* Premium members only.

The historical data trend for NovoCure's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Total Liabilities Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 729.00 750.48 783.63 880.61 463.86

NovoCure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 896.43 1,019.86 463.86 457.21 457.10
NVCR
70GF Score
NovoCure Ltd NVCR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NovoCure's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=223.228+(236.694+1.6431300764452E-14
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+3.938+0)
=463.9

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=804.326-340.466
=463.9

NovoCure's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=220.71+(233.42+-5.7731597280508E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+2.969+0)
=457.1

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=795.191-338.092
=457.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $457.1 Mil mean?
NovoCure (NVCR) has a Total Liabilities of $457.1 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NovoCure and its competitors.
Is NovoCure's Total Liabilities too high?
NovoCure's current Total Liabilities is $457.1 Mil. Overall, NovoCure has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Total Liabilities compare to NEOG and AXGN?
NovoCure's Total Liabilities of $457.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NovoCure and its competitors. NovoCure's current Total Liabilities is $457.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (NVCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.29, compared to a current price of $15.68 — trading 14.3% below its estimated fair value. The current Total Liabilities is $457.1 Mil. NovoCure's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For NovoCure (NVCR), the current Total Liabilities is $457.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (NVCR) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of $15.68 is trading 14.3% below its estimated GF Value™ of $18.29. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for NVCR:

  • Total Liabilities: $457.1 Mil
  • GF Value™: $18.29 vs. price of $15.68 (14.3% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the NVCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score

Get the complete analysis for NVCR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.68
Price
$18.29
GF Value